Press Releases
10/10/11: MicroPhage Partners with Cardinal Health on Funding, Marketing First One-Day Susceptibility Test
LONGMONT, CO: October 10, 2011 – MicroPhage, Inc., developers of quick, easy-to-use diagnostic products for bacterial identification and antibiotic susceptibility and resistance testing, announced today it has reached an agreement with Cardinal Health granting exclusive rights to market the KeyPath™ MRSA/MSSA Blood Culture Test product line in North America. Full release...
5/11/11: MicroPhage Announces the Formation of Its Medical Advisory Board
LONGMONT, CO: May 11, 2011 – MicroPhage Inc. announced today that it has formed a Medical Advisory Board to guide the Company as it moves into the commercialization phase of its novel diagnostic technology. The board is comprised of four internationally recognized clinicians in the field of pathogenic bacteria and antibiotic susceptibility. Richard Proctor, MD, will chair the committee. Full release...
5/6/11: FDA clears first test to quickly diagnose and distinguish MRSA and MSSA – May 2011
The U.S. Food and Drug Administration today cleared the first test for Staphylococcus aureus (S.aureus) infections that is able to quickly identify whether the bacteria are methicillin resistant (MRSA) or methicillin susceptible (MSSA). Full release...
5/6/11: FDA Clears First One-Day Susceptibility Test for Diagnosis of Deadly Bacteria
MicroPhage, Inc., developers of quick easy-to-use diagnostic products for bacterial identification, antibiotic susceptibility and resistance testing, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration to market its KeyPath™ MRSA/MSSA Blood Culture Test – BT, which returns same-day antibiotic susceptibility results for deadly S. aureus infections. Full release...
01/10/2011: MicroPhage names Don Mooney to Serve as New CEO
LONGMONT, CO, January 10, 2011 – MicroPhage, Inc. announced today that Don Mooney has been named as the new Chief Executive Officer of the company and assumes the role effective February 3, 2011. Full release...
11/02/2010: MicroPhage Awarded $978,000 for Development of Bacterial Diagnostic Tests LONGMONT, CO, November 2, 2010 – MicroPhage, Inc. announced today that it has received Qualifying Therapeutic Discovery Project (QTDP) grants of $977,916 from the IRS. Full release...
09/30/2010: MicroPhage names Mel Schatz to Board of Directors
LONGMONT, CO: September 30, 2010 – MicroPhage announced today that Mel Schatz has been named to the company's board of directors. Mr. Schatz is an experienced
industry executive and has held senior leadership positions at Abbott Diagnostics, Medtronic, Bacchus Vascular and is the current President and CEO of at Crux Biomedical. Full release...
07/14/2010: MicroPhage wins 'R&D Magazine 100 Award' for world's first test designed to rapidly identify bacterial infections and determine antibiotic susceptibility
LONGMONT, CO: July 14, 2010 – MicroPhage announced today that it has received the 'R&D Magazine 100 Award' in Bioscience for its 'Microphage MRSA/MSSA Blood Culture
Test.' Full release...
05/24/2010: MicroPhage launches world’s first diagnostics for antibiotic testing and bacterial identification in just five hours
LONGMONT, CO: May 24, 2010 – MicroPhage announced today the launch of its new diagnostic platform at the 110th Annual General Meeting of the American Society for Microbiology (ASM)
in San Diego. Full release...
01/12/2010: MicroPhage concludes pivotal clinical study
LONGMONT, CO: Jan. 12, 2010 – MicroPhage announced today that it has concluded a pivotal study of the ‘MicroPhage MRSA/MSSA Blood Culture Test’, the first of its instrument-free, rapid tests based on patented Bacteriophage Amplification technology. Full release…
12/07/2009: MicroPhage obtains CE Mark to sell world’s first rapid MRSA/MSSA test in Europe
LONGMONT, CO: Dec. 7, 2009 – MicroPhage announced today that it has obtained its CE Mark to market in Europe the first of its instrument-free, rapid tests based on its patented Bacteriophage Amplification technology. Full release…
10/12/2009: Former Premier CEO Richard Norling to Join MicroPhage Board of Directors
LONGMONT, CO: October 12, 2009 – MicroPhage Inc. today announced it named Richard (Rick) Norling to the Board of Directors. Mr. Norling served as President and Chief Executive Officer of Premier Inc., the largest healthcare alliance in the United States, from 1997 until June 2009. Full release...
08/19/2009: MicroPhage Opens Pivotal FDA Study on Bacterial Identification Platform
LONGMONT, CO: August 19, 2009 – MicroPhage announced today the launch of its multi-site clinical trial to
support a US Food and Drug Administration (FDA) premarket notification [510(k)]. The platform has been
developed to rapidly identify bacterial infections and determine antibiotic susceptibility or resistance to aid
physicians in antibiotic management. Full release...
05/28/2009: MicroPhage Doubles Offices and Laboratories, Eyes Future Growth, Despite Economy
LONGMONT, CO., May 28 – Despite the state of today’s economy, one rising star of Boulder County's burgeoning medical diagnostic community is growing. MicroPhage, Inc. announced today its expansion of its facilities in the Trade Centre park in Longmont to accommodate company expansion through 2009. Full release...
05/21/2009: MicroPhage Results on Rapid S. aureus/MRSA Blood Culture Test Published
LONGMONT, CO: May 21, 2009 – The performance of a new diagnostic test platform that rapidly identifies Staphylococcus aureus (S. aureus, “staph”) bacteremia and determines antibiotic resistance or susceptibility in as little as 5 hours was presented at the 109th General Meeting of the American Society of Microbiology in Philadelphia, PA this week. Full release...
05/18/2009: MicroPhage demonstrates rapid diagnostic platform feasibility in Skin and Soft Tissue infections.
PHILADELPHIA, PA: May 18, 2009 – In a presentation at the current General Meeting of the American Society for Microbiology (ASM) being held in Philadelphia, PA, a simple and inexpensive developmental diagnostic assay produced by MicroPhage, Inc., www.microphage.com, was shown to be highly accurate for rapid identification of serious staph bacterial infections from skin and soft tissue infections. Full release...
01/12/2009: MicroPhage Successfully Completes Beta Trial for Rapid MRSA Test
LONGMONT, CO: Jan. 12, 2009 – A new bacterial identification test that rapidly identifies MRSA infections moved closer to market with conclusion of its first multicenter clinical trial, announced today by MicroPhage, Inc., www.microphage.com. The company also reported that the trial results have surpassed its early-stage performance expectations. Full release...
11/18/2008: New Research Shows MicroPhage Test Accurately and Rapidly Detects Serious Bacterial Infections
LONGMONT, CO: Nov. 18, 2008 – A simple and inexpensive developmental diagnostic assay produced by MicroPhage, Inc., www.microphage.com, was shown to be highly accurate for rapid detection of serious staph bacteria infections and for simultaneous assessment of antibiotic susceptibility. The research was reported in three scientific presentations at the recent Interscience Conference on Anti-microbial Agents and Chemotherapy (ICAAC). Full release...
11/19/2008: MicroPhage Closes Latest Financing
LONGMONT, CO: Nov.19, 2008 – MicroPhage, Inc., www.microphage.com, today announced it has concluded its latest round of financing, which brings total capital raised to $11 million. Investors in this round were a combination of existing and new investors. All funds to date have come from private investors. Full release...